At 10:00 AM NACST Time on April 24, 2024, ASCO announced the highly anticipated Late-Breaking Abstract (LBA) selections for its annual meeting. Among them, the study titled “Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study” was selected as an LBA.The official LBA presentation will be released on June 2, when Professor Zhao Weili from Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, will provide a detailed interpretation of the DEB study’s interim results, sharing the latest progress on Chidamide in treating diffuse large B-cell lymphoma.

The ASCO Annual Meeting (American Society of Clinical Oncology) is the world’s premier oncology event, bringing together experts, physicians, and researchers from around the globe to share cutting-edge research, explore novel treatment strategies and technologies, and advance scientific progress in cancer care. The meeting typically features clinical study reports, oral and poster presentations, keynote lectures, educational sessions, and symposia. Among these, Late-Breaking Abstracts (LBAs) showcase the most influential research of the year, often with the potential to reshape clinical practice. ASCO strictly maintains confidentiality of LBA data until their official presentation. The LBA titled “Tucidinostat plus R-CHOP in Previously Untreated Diffuse Large B-cell Lymphoma with Double Expression of MYC and BCL2: Interim Analysis of the Phase III DEB Study” represents a significant recognition by the international oncology community of the outstanding contributions of Chinese researchers. It also highlights the remarkable clinical value of China’s original drug, Chidamide.

In addition, Chidamide has shown significant progress in clinical studies across multiple oncology indications. Highlights include Professor Zhang Yizhuo from Sun Yat-sen University Cancer Center investigating Chidamide for neuroblastoma, Professor Mao Lili from Beijing Cancer Hospital studying Chidamide for melanoma, Professor Wang Tao from The Fifth Medical Center of the Chinese PLA General Hospital exploring Chidamide for advanced breast cancer, Professor Li Wei from The First Affiliated Hospital of Soochow University conducting a clinical trial of Chidamide for advanced colorectal cancer. These studies further underscore Chidamide’s broad therapeutic potential across a wide range of tumor types.

(1) Title: Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study
Abstract Number: LBA7003
Type: LBA + Oral Abstract Session
Presenter: Zhao WeiLi (Ruijin Hospital, Shanghai Jiao Tong University School of Medicine)
Presentation Time: 16:00-16:12

(2) Title: Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II study
Abstract Number: e21527
Type: Publication Only
First Author: Mao Lili (Beijing Cancer Hospital)

(3) Title: Phase I trial of chidamide, an oral HDAC inhibitor, in combination with oral etoposide in patients with refractory/recurrent neuroblastoma
Abstract Number: TPS3637
Type: Poster Session
Presenter: Zhang Yizhuo (Sun Yat-sen University Cancer Center)

(4) Title: Dalpiciclib and chidamide in patients with HR+/HER2- advanced breast cancer and resistance to CDK4/6 inhibitors: A phase lb trial.
Abstract Number: e13072
Type: Publication Only
First Author: Wang Tao (The Fifth Medical Center of the Chinese PLA General Hospital)

(5) Title: Efficacy and safety of chidamide in combination with serplulimab and standard third-line treatments in advanced colorectal cancer: A single arm, exploratory phase 2 trial.
Abstract Number: TPS3637
Type: Poster Session
Presenter: Li Wei (The First Affiliated Hospital of Soochow University)